Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo targets Hard-to-Treat cancers with MTAP deletion

NCT ID NCT06188702

Ongoing Disease control Sponsor: Servier Bio-Innovation LLC Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing a new oral drug called S095035, alone or combined with another drug (TNG462), in 60 adults with advanced solid tumors that have a specific genetic deletion (MTAP). These cancers have not responded to at least one prior treatment. The study aims to check safety, tolerability, and whether the drugs can shrink tumors. It is currently active but not recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
S095035 (MAT2A inhibitor) and TNG462 (PRMT5 inhibitor)
What this could lead to
If successful, this could lead to a new treatment option for people with certain advanced solid tumors that have a specific genetic deletion (MTAP) and have stopped responding to other therapies.
What could go wrong
This is an early (Phase 1/2) and small trial (60 people), so the drug may not work or could cause serious side effects. It is only for tumors with a specific genetic change, limiting who can benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

biliary tract cancer Biliary Tract Neoplasms IDH-wildtype glioblastoma non-small cell lung carcinoma pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MTAP-DELETED SOLID TUMORS

Contacts and locations

Locations

  • Aichi Cancer Center

    Aichi, 4648681, Japan

  • Centre Georges-François Leclerc

    Dijon, 21079, France

  • Community Health Network

    Indianapolis, Indiana, 46250, United States

  • Hospital Universitario Fundación Jiménez Díaz

    Madrid, 28040, Spain

  • Hôpital de la Timone (Marseille)

    Marseille, 13385, France

  • Institut Bergonié

    Bordeaux, 33076, France

  • Institut Gustave Roussy

    Paris, 94805, France

  • Instituto Clinico Humanitas Irccs

    Rozzano, 20098, Italy

  • Istituto Europeo Di Oncologia

    Milan, 20141, Italy

  • Lake Mary Cancer Center - Florida Cancer Specialists & Research Institute

    Lake Mary, Florida, 32746, United States

  • NEXT Oncology

    Austin, Texas, 78758, United States

  • National Hospital Organization Shikoku Cancer Center

    Ehime, 7910280, Japan

  • Policlinico G.B. Rossi A.O.U.I. Di Verona

    Verona, 37134, Italy

  • Royal Hobart Hospital

    Hobart, 7000, Australia

  • SCRI Oncology Partners

    Nashville, Tennessee, 37203, United States

  • Scientia Clinical Research

    Randwick, New South Wales, 2031, Australia

  • Start Madrid Group - Hm Ciocc

    Madrid, 28050, Spain

  • Taylor Cancer Research Center

    Maumee, Ohio, 43537, United States

  • The Alfred

    Prahran, Victoria, 3004, Australia

  • The Cancer Institute Hospital of JFCR

    Tokyo, 1358550, Japan

  • Townsville University Hospital

    Douglas, 4812, Australia

  • Universitätsklinikum Ulm

    Ulm, 89081, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.